Suven Life Sciences Ltd has secured patents in Australia, Canada, Japan and New Zealand for one of its new chemical entity (NCE) for CNS therapy through new mechanism of action – H3 Inverse agonist. The granted claims of the patent - which is valid until 2030 - include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
Histaminargic dysfunction has been strongly associated with the cognitive and behavioural deficits observed in several CNS disorders such as Alzheimer’s, ADHD, dementia, depression, Huntington’s disease and Parkinson’s disease. H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offer a means for targeting cognitive processes. Novel, potent, selective, brain penetrant and orally active H 3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for this unmet medical need.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.
With these new patents, Suven has a total of 20 granted patents from Australia, 17 granted patents from Canada, 15 granted patents from Japan and 22 granted patents from New Zealand. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase I or Phase II.
Histaminargic dysfunction has been strongly associated with the cognitive and behavioural deficits observed in several CNS disorders such as Alzheimer’s, ADHD, dementia, depression, Huntington’s disease and Parkinson’s disease. H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offer a means for targeting cognitive processes. Novel, potent, selective, brain penetrant and orally active H 3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for this unmet medical need.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.
With these new patents, Suven has a total of 20 granted patents from Australia, 17 granted patents from Canada, 15 granted patents from Japan and 22 granted patents from New Zealand. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase I or Phase II.